268 related articles for article (PubMed ID: 33985991)
21. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
Milliner D; Hoppe B; Groothoff J
Urolithiasis; 2018 Aug; 46(4):313-323. PubMed ID: 28718073
[TBL] [Abstract][Full Text] [Related]
22. Lumasiran treatment in pediatric patients with PH1: real-world data within a compassionate use program in Italy.
Taroni F; Peruzzi L; Longo G; Becherucci F; Malgieri G; D'Alessandro MM; Montini G
Clin Kidney J; 2024 May; 17(5):sfae090. PubMed ID: 38742209
[TBL] [Abstract][Full Text] [Related]
23. Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1.
Martin-Higueras C; Borghese L; Torres A; Fraga-Bilbao F; Santana-Estupiñán R; Stefanidis CJ; Tory K; Walli A; Gondra L; Kempf C; Gessner M; Habbig S; Eifler L; Schmitt CP; Rüdel B; Bartram MP; Beck BB; Hoppe B
Kidney Int Rep; 2024 Jan; 9(1):114-133. PubMed ID: 38312792
[TBL] [Abstract][Full Text] [Related]
24. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
Liebow A; Li X; Racie T; Hettinger J; Bettencourt BR; Najafian N; Haslett P; Fitzgerald K; Holmes RP; Erbe D; Querbes W; Knight J
J Am Soc Nephrol; 2017 Feb; 28(2):494-503. PubMed ID: 27432743
[TBL] [Abstract][Full Text] [Related]
25. A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria.
Goldfarb DS; Modersitzki F; Asplin JR
Clin J Am Soc Nephrol; 2007 Jul; 2(4):745-9. PubMed ID: 17699491
[TBL] [Abstract][Full Text] [Related]
26. Lumasiran for primary hyperoxaluria type 1: What we have learned?
Gang X; Liu F; Mao J
Front Pediatr; 2022; 10():1052625. PubMed ID: 36704142
[TBL] [Abstract][Full Text] [Related]
27. Infantile Primary Hyperoxaluria Type 1 Treated With Lumasiran in Twin Males.
Aldabek K; Grossman OK; Al-Omar O; Fox JA; Moritz ML
Cureus; 2022 Jan; 14(1):e21673. PubMed ID: 35237473
[TBL] [Abstract][Full Text] [Related]
28. A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme.
Langman CB; Grujic D; Pease RM; Easter L; Nezzer J; Margolin A; Brettman L
Am J Nephrol; 2016; 44(2):150-8. PubMed ID: 27529510
[TBL] [Abstract][Full Text] [Related]
29. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1.
Hoppe B; Beck B; Gatter N; von Unruh G; Tischer A; Hesse A; Laube N; Kaul P; Sidhu H
Kidney Int; 2006 Oct; 70(7):1305-11. PubMed ID: 16850020
[TBL] [Abstract][Full Text] [Related]
30. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2.
Baum MA; Langman C; Cochat P; Lieske JC; Moochhala SH; Hamamoto S; Satoh H; Mourani C; Ariceta G; Torres A; Wolley M; Belostotsky V; Forbes TA; Groothoff J; Hayes W; Tönshoff B; Takayama T; Rosskamp R; Russell K; Zhou J; Amrite A; Hoppe B;
Kidney Int; 2023 Jan; 103(1):207-217. PubMed ID: 36007597
[TBL] [Abstract][Full Text] [Related]
31. A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
Hoppe B; Niaudet P; Salomon R; Harambat J; Hulton SA; Van't Hoff W; Moochhala SH; Deschênes G; Lindner E; Sjögren A; Cochat P
Pediatr Nephrol; 2017 May; 32(5):781-790. PubMed ID: 27924398
[TBL] [Abstract][Full Text] [Related]
32. Case Report: effect of lumasiran treatment in a late preterm baby with antenatal diagnosis of primary hyperoxaluria type 1.
Taroni F; Berrettini A; Gnech M; Rella F; Manzoni GA; Montini G
Front Pediatr; 2023; 11():1338909. PubMed ID: 38293660
[TBL] [Abstract][Full Text] [Related]
33. The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria.
Buchalski B; Wood KD; Challa A; Fargue S; Holmes RP; Lowther WT; Knight J
Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165633. PubMed ID: 31821850
[TBL] [Abstract][Full Text] [Related]
34. Glycolate oxidase inhibition by lumasiran varies between patients with primary hyperoxaluria type 1.
Garrelfs SF; Metry EL; van Harskamp D; Vaz FM; van den Akker CHP; Schierbeek H; Groothoff JW; Oosterveld MJS
Kidney Int; 2023 May; 103(5):990-993. PubMed ID: 36871948
[No Abstract] [Full Text] [Related]
35. Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review.
Demoulin N; Aydin S; Gillion V; Morelle J; Jadoul M
Am J Kidney Dis; 2022 May; 79(5):717-727. PubMed ID: 34508834
[TBL] [Abstract][Full Text] [Related]
36. Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).
Goldfarb DS; Lieske JC; Groothoff J; Schalk G; Russell K; Yu S; Vrhnjak B
Urolithiasis; 2023 Apr; 51(1):80. PubMed ID: 37118061
[TBL] [Abstract][Full Text] [Related]
37. Glycolate determination detects type I primary hyperoxaluria in dialysis patients.
Marangella M; Petrarulo M; Bianco O; Vitale C; Finocchiaro P; Linari F
Kidney Int; 1991 Jan; 39(1):149-54. PubMed ID: 2002628
[TBL] [Abstract][Full Text] [Related]
38. Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.
Chetyrkin SV; Kim D; Belmont JM; Scheinman JI; Hudson BG; Voziyan PA
Kidney Int; 2005 Jan; 67(1):53-60. PubMed ID: 15610227
[TBL] [Abstract][Full Text] [Related]
39. Plasma and urine glycolate assays for differentiating the hyperoxaluria syndromes.
Marangella M; Petrarulo M; Vitale C; Cosseddu D; Linari F
J Urol; 1992 Sep; 148(3 Pt 2):986-9. PubMed ID: 1507356
[TBL] [Abstract][Full Text] [Related]
40. Progress with RNA Interference for the Treatment of Primary Hyperoxaluria.
Sawyer K; Leahy S; Wood KD
BioDrugs; 2022 Jul; 36(4):437-441. PubMed ID: 35731461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
